ABSTRACT
In this work we use mathematical modeling to describe one possible route to the end of COVID-19, which does not feature either vaccination or herd immunity. We consider a region where the following conditions hold true : (a) there is no influx of cases from the outside, (b) there is extensive social distancing, though not necessarily a full lockdown, so that mass transmission events do not occur, and (c) testing capacity is high relative to the actual number of new cases per day. These conditions can make it possible for the region to initiate the endgame phase of epidemic management, wherein the virus is slowly starved of new targets through a combination of social distancing, sanitization, contact tracing and extensive testing. The dynamics of the cases in this regime is governed by a single-variable first order linear delay differential equation, whose stability criterion can be obtained explicitly. Analysis of the equation can tell us which social restrictions may be relaxed during the endgame, and which may not. For example, in an academic institution, a small research group might be allowed to meet in person once a week while classroom instruction should remain fully suspended. If the endgame can be played out for a long enough time, we claim that the disease can eventually get completely contained without affecting a significant fraction of the region’s population. We present estimates of the duration for which the epidemic is expected to last, finding an interval of approximately 5-15 weeks after the endgame strategy is initiated.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
We have NOT received funding for this study from any agency.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.